Lanean...
One-year outcomes of Aflibercept for refractory diabetic macular edema in Bevacizumab nonresponders
PURPOSE: A sub-population of patients with diabetic macular edema (DME) responds less effectively to off-label use of Bevacizumab. Approval of Aflibercept for DME has offered Bevacizumab nonresponders an alternative therapeutic option. Herein, we investigate the anatomical and functional changes ass...
Gorde:
| Argitaratua izan da: | Indian J Ophthalmol |
|---|---|
| Egile Nagusiak: | , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Wolters Kluwer - Medknow
2021
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7933844/ https://ncbi.nlm.nih.gov/pubmed/33463593 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/ijo.IJO_459_20 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|